Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 17/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 14/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.43 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20442141 | 0.89 | ADORA2A (0.44) | ADORA2AADORA2BADORA1KLKB1 | |
| SCHEMBL23675861 | 0.89 | ADORA2A (0.44) | ADORA2AADORA2BADORA1KLKB1 | |
| SCHEMBL20416584 | 0.87 | ADORA2A (0.46) | ADORA2AADORA2BADORA1KLKB1 | |
| SCHEMBL30401852 | 0.87 | ADORA2A (0.46) | ADORA2AADORA2BADORA1KLKB1 | |
| SCHEMBL23675864 | 0.86 | ADORA2A (0.43) | ADORA2AADORA2BADORA1KLKB1 | |
| SCHEMBL20436436 | 0.84 | ADORA2A (0.47) | ADORA2AADORA2BADORA1 | |
| SCHEMBL20442138 | 0.84 | ADORA2A (0.49) | ADORA2AADORA2BADORA1 | |
| SCHEMBL20442170 | 0.84 | ADORA2A (0.49) | ADORA2AADORA2BADORA1 | |
| SCHEMBL30401511 | 0.84 | ADORA2A (0.49) | ADORA2AADORA2BADORA1 | |
| SCHEMBL20400627 | 0.84 | ADORA2A (0.49) | ADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144808-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ARCUS BIOSCIENCES, INC. | 2022-05-12 | — | — | US | disclosed |
| US-11072597-B2 | Azolopyrimidine for the treatment of cancer-related disorders | ARCUS BIOSCIENCES, INC. | 2021-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144808-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ADORA2A, ADORA2B, ADORA1 | ADORA2A 1/4885ADORA2B 2/4885ADORA1 3/4885 |
| US-11072597-B2 | Azolopyrimidine for the treatment of cancer-related disorders | ADORA2A, ADORA2B, ADORA1 | ADORA2A 1/4885ADORA2B 2/4885ADORA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.